Biomodex, a Paris, France- and Boston, MA-based medical device company that uses 3D printing technology to develop patient-specific synthetic organs for pre-operative planning, raised an additional $15m in Series A funding.
The round, which brings total financing to more than $18.5m, was led by Idinvest Partners and InnovAllianz with participation of pre-existing investors, LBO France and Inserm Transfert Initiative.
The company intends to use the funds to develop new products in the interventional cardiology space, and enable the opening of a new manufacturing facility outside Boston, Massachusetts.
Led by Thomas Marchand, CEO, Biomodex has developed patented technology that enables the 3D printing of organs based on medical imaging, such as a CT Scan or Echo. By combining 3D printing with the technology, the company is able to produce the biomechanics of the organ and surrounding tissue, mimicking the patient-specific biomechanical properties and behavior with a quick turnaround time.
To date, the solution has been used primarily for interventional neuroradiology applications with demand coming from the cariological space as well.